New York State Common Retirement Fund Lowers Position in SI-BONE, Inc. (NASDAQ:SIBN)

New York State Common Retirement Fund lowered its holdings in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 80.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,436 shares of the company's stock after selling 302,507 shares during the period. New York State Common Retirement Fund owned approximately 0.18% of SI-BONE worth $1,562,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. RiverPark Advisors LLC bought a new position in SI-BONE in the 3rd quarter worth approximately $55,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of SI-BONE by 48.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,435 shares of the company's stock valued at $158,000 after purchasing an additional 2,437 shares in the last quarter. Arizona State Retirement System raised its holdings in SI-BONE by 7.7% during the 4th quarter. Arizona State Retirement System now owns 10,675 shares of the company's stock worth $224,000 after buying an additional 762 shares during the period. HighMark Wealth Management LLC purchased a new position in SI-BONE during the fourth quarter valued at approximately $399,000. Finally, Glenmede Trust Co. NA purchased a new position in shares of SI-BONE during the 3rd quarter valued at $417,000. Institutional investors and hedge funds own 98.11% of the company's stock.

Insider Buying and Selling

In other SI-BONE news, CFO Anshul Maheshwari sold 2,425 shares of the business's stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total transaction of $37,466.25. Following the completion of the sale, the chief financial officer now directly owns 205,516 shares of the company's stock, valued at approximately $3,175,222.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Anthony J. Recupero sold 3,307 shares of SI-BONE stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $15.50, for a total value of $51,258.50. Following the completion of the transaction, the insider now directly owns 252,453 shares in the company, valued at approximately $3,913,021.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Anshul Maheshwari sold 2,425 shares of SI-BONE stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $15.45, for a total value of $37,466.25. Following the completion of the transaction, the chief financial officer now owns 205,516 shares of the company's stock, valued at $3,175,222.20. The disclosure for this sale can be found here. Insiders sold 11,905 shares of company stock valued at $190,273 over the last 90 days. Company insiders own 5.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price objective on shares of SI-BONE in a research note on Tuesday, February 27th. Morgan Stanley reduced their price objective on SI-BONE from $26.00 to $25.00 and set an "overweight" rating for the company in a research report on Tuesday. Needham & Company LLC restated a "buy" rating and issued a $27.00 price objective on shares of SI-BONE in a research note on Tuesday. Piper Sandler assumed coverage on SI-BONE in a report on Thursday, March 28th. They set an "overweight" rating and a $25.00 price objective on the stock. Finally, Truist Financial reiterated a "buy" rating and issued a $24.00 price target (down from $26.00) on shares of SI-BONE in a research report on Tuesday, February 27th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, SI-BONE has an average rating of "Buy" and an average target price of $27.29.

SI-BONE Stock Down 1.4 %

Shares of NASDAQ:SIBN traded down $0.21 during trading on Friday, hitting $15.33. 449,563 shares of the company were exchanged, compared to its average volume of 436,706. The stock has a market cap of $631.66 million, a price-to-earnings ratio of -14.26 and a beta of 1.24. The company has a current ratio of 9.01, a quick ratio of 8.15 and a debt-to-equity ratio of 0.21. SI-BONE, Inc. has a fifty-two week low of $13.96 and a fifty-two week high of $29.51. The firm has a fifty day moving average price of $15.74 and a two-hundred day moving average price of $17.97.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.02. The company had revenue of $38.86 million during the quarter, compared to analysts' expectations of $38.60 million. SI-BONE had a negative return on equity of 28.22% and a negative net margin of 31.20%. As a group, research analysts anticipate that SI-BONE, Inc. will post -0.98 earnings per share for the current fiscal year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.